ALX Oncology (ALXO)

• Market cap: $85.1M
• 1 day: 3.25%
• 5 days: -3.64%
• 1 month: -9.14%
• 3 months: 174.14%
• 6 months: 211.76%
• Year to date: 1.92%
• 1 year: 13.57%
• 5 years: -96.02%
• 10 years: -94.7%
• Sector: Healthcare
• Industry: Biotechnology

About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Employees: 49